BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

For intramuscular use only.

2.1 Dose and Schedule

Administer 2 doses (0.5-mL each) of BEXSERO at least 1 month apart.
2.2 Administration
Shake the syringe immediately before use to form a homogeneous suspension. Do not use the vaccine if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter or discoloration is found.
Administer BEXSERO as a 0.5-mL intramuscular injection into the deltoid muscle of the upper arm.

2.3 Use of BEXSERO with Other Meningococcal Group B Vaccines
Sufficient data are not available on the safety and effectiveness of using BEXSERO and other meningococcal group B vaccines interchangeably to complete the vaccination series.

3 DOSAGE FORMS AND STRENGTHS
BEXSERO is a suspension for intramuscular injection in 0.5-mL prefilled TIP-LOK syringes.

4 CONTRAINDICATIONS
Hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO [see Description (11)].

5 WARNINGS AND PRECAUTIONS
5.1 Preventing and Managing Allergic Reactions
Appropriate observation and medical treatment should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.

5.2 Syncope
Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope.

5.3 Limitation of Vaccine Effectiveness
BEXSERO may not protect all vaccine recipients. BEXSERO may not provide protection against all meningococcal serogroup B strains [see Clinical Pharmacology (12.1)].

5.4 Altered Immunocompetence
Some individuals with altered immunocompetence may have reduced immune responses to BEXSERO.

Complement Deficiency
Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive
disease caused by *N. meningitidis* serogroup B even if they develop antibodies following vaccination with BEXSERO. [See Clinical Pharmacology (12.1).]

6 ADVERSE REACTIONS

The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%).

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared with rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

In 4 clinical trials, 3,058 individuals aged 10 through 25 years received at least one dose of BEXSERO, 1,436 participants received only BEXSERO, 2,089 received only placebo or a control vaccine, and 1,622 participants received a mixed regimen (placebo or control vaccine and BEXSERO).

In a randomized controlled study\(^1\) conducted in U.S. and Poland, 120 participants aged 10 through 25 years received at least 1 dose of BEXSERO, including 112 participants who received 2 doses of BEXSERO 2 months apart; 97 participants received saline placebo followed by MENVEO [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diphtheria CRM\(_{197}\) Conjugate Vaccine]. Across groups, median age was 13 years, males comprised 49%, and 60% were White, 34% were Hispanic, 4% were Black, <1% were Asian, and 2% were other.

In a second randomized controlled study\(^2\) conducted in Chile, all subjects (N = 1,622) aged 11 through 17 years received at least 1 dose of BEXSERO. This study included a subset of 810 subjects who received 2 doses of BEXSERO 1 or 2 months apart. A control group of 128 subjects received at least 1 dose of placebo containing aluminum hydroxide. A subgroup of 128 subjects received 2 doses of BEXSERO 6 months apart. In this study, median age was 14 years, males comprised 44%, and 99% were Hispanic.

In a third randomized controlled study\(^3\) conducted in the United Kingdom (U.K.), 974 university students aged 18 through 24 years received at least 1 dose of BEXSERO, including 932 subjects who received 2 doses of BEXSERO 1 month apart. Comparator groups received 1 dose of MENVEO followed by 1 dose of placebo containing aluminum hydroxide (n = 956) or 2 doses of IXIARO (Japanese Encephalitis Vaccine, Inactivated, Adsorbed) (n = 947). Across groups, median age was 20 years, males comprised 46%, and 88% were White, 5% were Asian, 2% were Black, <1% were Hispanic, and 4% were other.

In an uncontrolled study\(^4\) conducted in Canada and Australia, 342 participants aged 11 through 17 years received at least 1 dose of BEXSERO, including 338 participants who received 2 doses
of BEXSERO 1 month apart. The median age was 13 years, males comprised 55%, and 80% were White, 10% were Asian, 4% were Native American/Alaskan, and 4% were other.

Local and systemic reactogenicity data were solicited from all participants in the studies conducted in Chile, U.S./Poland, Canada/Australia, and in a subset of participants in the U.K. study. Reports of unsolicited adverse events occurring within the first 7 days after each vaccination were collected in all studies. In the U.S./Poland study, reports of unsolicited adverse events were collected up to 1 month after the second vaccination.

Reports of all serious adverse events, medically attended adverse events, and adverse events leading to premature withdrawal were collected throughout the study period for the studies conducted in Chile (12 months), U.K. (12 months), U.S./Poland (8 months), and Canada/Australia (2 months).

Solicited Adverse Reactions

The reported rates of local and systemic reactions among participants aged 10 through 25 years following each dose of BEXSERO administered 2 months apart or control in the U.S./Polish study have been presented in Table 1.

Table 1. Percentage of U.S. and Polish Participants Aged 10 through 25 Years Reporting Solicited Local and Systemic Adverse Reactions within 7 Days after BEXSERO or Control, by Dose

<table>
<thead>
<tr>
<th>Solicited Reactiona</th>
<th>Dose 1</th>
<th>Dose 2b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BEXSERO (Saline)</td>
<td>BEXSERO</td>
</tr>
<tr>
<td></td>
<td>n = 110-114</td>
<td>n = 94-96</td>
</tr>
</tbody>
</table>

Local Adverse Reactions

<table>
<thead>
<tr>
<th>Solicited Reactiona</th>
<th>Dose 1</th>
<th>Dose 2b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BEXSERO (Saline)</td>
<td>BEXSERO</td>
</tr>
<tr>
<td></td>
<td>n = 110-114</td>
<td>n = 94-96</td>
</tr>
</tbody>
</table>

Pain

- Any: 90, 27, 83, 43
- Mild: 27, 20, 18, 26
- Moderate: 44, 5, 37, 9
- Severe: 20, 2, 29, 8

Erythema

- Any: 50, 13, 45, 26
- 1-25 mm: 41, 11, 36, 13
- >25-50 mm: 6, 1, 5, 6
- >50-100 mm: 3, 0, 5, 4
- >100 mm: 0, 0, 0, 2

Induration

- Any: 32, 10, 28, 23
- 1-25 mm: 24, 9, 22, 16
<table>
<thead>
<tr>
<th></th>
<th>&gt;25-50 mm</th>
<th>&gt;50-100 mm</th>
<th>&gt;100 mm</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Systemic Adverse Reactions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>7</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Mild</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Moderate</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Severe</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>19</td>
<td>4</td>
<td>18</td>
</tr>
<tr>
<td>Mild</td>
<td>12</td>
<td>3</td>
<td>10</td>
</tr>
<tr>
<td>Moderate</td>
<td>4</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Severe</td>
<td>4</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Myalgia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>49</td>
<td>26</td>
<td>48</td>
</tr>
<tr>
<td>Mild</td>
<td>21</td>
<td>20</td>
<td>16</td>
</tr>
<tr>
<td>Moderate</td>
<td>16</td>
<td>5</td>
<td>19</td>
</tr>
<tr>
<td>Severe</td>
<td>12</td>
<td>1</td>
<td>13</td>
</tr>
<tr>
<td>Arthralgia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>13</td>
<td>4</td>
<td>16</td>
</tr>
<tr>
<td>Mild</td>
<td>9</td>
<td>3</td>
<td>8</td>
</tr>
<tr>
<td>Moderate</td>
<td>3</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Severe</td>
<td>2</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Headache</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>33</td>
<td>20</td>
<td>34</td>
</tr>
<tr>
<td>Mild</td>
<td>19</td>
<td>15</td>
<td>21</td>
</tr>
<tr>
<td>Moderate</td>
<td>9</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Severe</td>
<td>4</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>Fever</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥38°C</td>
<td>1</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>38.0-38.9°C</td>
<td>1</td>
<td>1</td>
<td>4</td>
</tr>
<tr>
<td>39.0-39.9°C</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>≥40°C</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Clinicaltrials.gov Identifier NCT01272180.

a Erythema and induration: Any (≥1 mm). Pain and systemic reactions: Mild (transient with no limitation in normal daily activity); Moderate (some limitation in normal daily activity); Severe (unable to perform normal daily activity).

b Administered 2 months after Dose 1.
Solicited adverse reaction rates were similar among participants aged 11 through 24 years who received BEXSERO in the other 3 clinical studies\textsuperscript{2,3,4}, except for severe myalgia which was reported by 3% to 7% of subjects. Severe pain was reported by 8% of university students in the U.K.\textsuperscript{3}

**Non-serious Adverse Reactions**

In the 3 controlled studies\textsuperscript{1,2,3} (BEXSERO n = 2,221, control n = 2,204), non-serious unsolicited adverse events that occurred within 7 days of any dose were reported by 439 (20%) participants receiving BEXSERO and 197 (9%) control recipients. Unsolicited adverse reactions that were reported among at least 2% of participants and were more frequently reported in participants receiving BEXSERO than in control recipients were injection site pain, headache, injection site induration unresolved within 7 days, and nasopharyngitis.

**Serious Adverse Events**

Overall, in clinical studies, among 3,058 participants aged 10 through 25 years who received at least 1 dose of BEXSERO, 66 (2.1%) participants reported serious adverse events at any time during the study. In the 3 controlled studies\textsuperscript{1,2,3} (BEXSERO n = 2,716, control n = 2,078), serious adverse events within 30 days after any dose were reported in 23 (0.8%) participants receiving BEXSERO and 10 (0.5%) control recipients.

**6.2 Additional Pre-licensure Safety Experience**

In response to outbreaks of serogroup B meningococcal disease at 2 universities in the U.S., BEXSERO was administered as a 2-dose series at least 1 month apart. Information on serious adverse events was collected for a period of 30 days after each dose from 15,351 individuals aged 16 through 65 years who received at least 1 dose. Overall, 50 individuals (0.3%) reported serious adverse events, including one reaction considered related to vaccination, a case of anaphylaxis within 30 minutes following vaccination.

**6.3 Postmarketing Experience**

The following adverse reactions have been identified during postapproval use of BEXSERO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.

**Blood and Lymphatic System Disorders**

Lymphadenopathy.

**General Disorders and Administration Site Conditions**

Injection site reactions (including extensive swelling of the vaccinated limb, blisters at or around the injection site, and injection site nodule which may persist for more than 1 month).

**Immune System Disorders**

Allergic reactions (including anaphylactic reactions), rash, eye swelling.
7 DRUG INTERACTIONS

Sufficient data are not available to establish the safety and immunogenicity of concomitant administration of BEXSERO with recommended adolescent vaccines.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

There are no adequate and well-controlled studies of BEXSERO in pregnant women in the U.S. Available human data on BEXSERO administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.

A developmental toxicity study was performed in female rabbits administered BEXSERO prior to mating and during gestation. The dose was 0.5 mL at each occasion (a single human dose is 0.5 mL). This study revealed no adverse effects on fetal or pre-weaning development due to BEXSERO (see Data).

Data

Animal Data: In a developmental toxicity study, female rabbits were administered BEXSERO by intramuscular injection on Days 29, 15, and 1 prior to mating and on Gestation Days 7 and 20. The total dose was 0.5 mL at each occasion (a single human dose is 0.5 mL). No adverse effects on pre-weaning development up to Postnatal Day 29 were observed. There were no fetal malformations or variations observed.

8.2 Lactation

Risk Summary

It is not known whether the vaccine components of BEXSERO are excreted in human milk. Available data are not sufficient to assess the effects of BEXSERO on the breastfed infant or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for BEXSERO and any potential adverse effects on the breastfed child from BEXSERO or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine.
8.4 Pediatric Use

Safety and effectiveness of BEXSERO have not been established in children younger than 10 years.

8.5 Geriatric Use

Safety and effectiveness of BEXSERO have not been established in adults older than 65 years.

11 DESCRIPTION

BEXSERO (Meningococcal Group B Vaccine) is a sterile, white, opalescent, suspension for intramuscular injection. Each 0.5-mL dose of BEXSERO is formulated to contain 50 micrograms each of recombinant proteins Neisserial adhesin A (NadA), Neisserial Heparin Binding Antigen (NHBA), and factor H binding protein (fHbp), 25 micrograms of Outer Membrane Vesicles (OMV), 1.5 mg aluminum hydroxide (0.519 mg of Al\(^{3+}\)), 3.125 mg sodium chloride, 0.776 mg histidine, and 10 mg sucrose at pH 6.4 to 6.7.

The NadA component is a fragment of the full-length protein derived from \textit{N. meningitidis} strain 2996 (peptide 8 variant 2/3). The NHBA component is a recombinant fusion protein comprised of NHBA (peptide 2) and accessory protein 953 derived from \textit{N. meningitidis} strains NZ98/254 and 2996, respectively. The fHbp component is a recombinant fusion protein comprised of fHbp (variant 1.1) and the accessory protein 936 derived from \textit{N. meningitidis} strains MC58 and 2996, respectively. These 3 recombinant proteins are individually produced in \textit{Escherichia coli} and purified through a series of column chromatography steps. The OMV antigenic component is produced by fermentation of \textit{N. meningitidis} strain NZ98/254 (expressing outer membrane protein Porin A [PorA] serosubtype P1.4), followed by inactivation of the bacteria by deoxycholate, which also mediates vesicle formation. The antigens are adsorbed onto aluminum hydroxide.

Each dose contains less than 0.01 micrograms kanamycin (by calculation).

The tip cap and rubber plunger stopper of the prefilled syringe are not made with natural rubber latex.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Protection against invasive meningococcal disease is conferred mainly by complement-mediated antibody-dependent killing of \textit{N. meningitidis}. The effectiveness of BEXSERO was assessed by measuring serum bactericidal activity using human complement (hSBA).

NHBA, NadA, fHbp, and PorA are proteins found on the surface of meningococci and contribute to the ability of the bacterium to cause disease. Vaccination with BEXSERO leads to the production of antibodies directed against NHBA, NadA, fHbp, and PorA P1.4 (present in OMV). The susceptibility of serogroup B meningococci to complement-mediated antibody-dependent
killing following vaccination with BEXSERO is dependent on both the antigenic similarity of the bacterial and vaccine antigens, as well as the amount of antigen expressed on the surface of the invading meningococci.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

BEXSERO has not been evaluated for carcinogenic or mutagenic potential or impairment of male fertility in animals. Vaccination of female rabbits with BEXSERO had no effect on fertility. [See Use in Specific Populations (8.1).]

14 CLINICAL STUDIES

The immunogenicity of BEXSERO following 2 doses was evaluated in individuals aged 11 through 24 years. Serum bactericidal antibodies were measured with hSBA assays using 3 strains selected to measure responses to one of 3 vaccine antigens, either fHbp, NadA, or PorA P1.4, prevalent among strains in the U.S. A suitable strain for assessing bactericidal activity of NHBA-specific antibodies was not available. Studies assessed the proportion of subjects who achieved a 4-fold or greater increase in hSBA titer for each of the 3 strains, and the proportion of subjects with a titer greater than or equal to the lower limit of quantitation (LLOQ) of the assay for all 3 strains (composite response). The LLOQ was defined as the lowest amount of the antibody in a sample that can be reliably quantified. Available data showed that baseline antibody titers across populations vary.

14.1 Immunogenicity

In a clinical trial conducted in Canada and Australia, adolescents aged 11 through 17 years received 2 doses of BEXSERO 1 month apart. The hSBA responses 1 month after the second dose are shown in Table 2.
Table 2. Bactericidal Antibody Response Rates following 2 Doses of BEXSERO Administered 1 Month Apart to Canadian and Australian Adolescents

<table>
<thead>
<tr>
<th>Strain (Antigen)</th>
<th>n</th>
<th>%</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>H44/76 (fHbp)</td>
<td>298</td>
<td>98</td>
<td>95, 99</td>
</tr>
<tr>
<td>5/99 (NadA)</td>
<td>299</td>
<td>99</td>
<td>98, 100</td>
</tr>
<tr>
<td>NZ98/254 (PorA P1.4)</td>
<td>298</td>
<td>39</td>
<td>33, 44</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Composite hSBA Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time Point</td>
</tr>
<tr>
<td>Baseline (pre-vaccination)</td>
</tr>
<tr>
<td>1 Month post-dose 2</td>
</tr>
</tbody>
</table>

NCT01423084.

hSBA = Serum bactericidal activity measured using human complement, CI = Confidence Interval, fHbp = factor H binding protein, NadA = Neisserial adhesin A, PorA = Porin A protein, LLOQ = Lower limit of quantitation.

School immunogenicity population (aged 11 through 17 years).

≥4-fold hSBA response is defined as: a post-vaccination hSBA ≥1:16 for participants with pre-vaccination hSBA <1:4, a post-vaccination titer at least 4-fold the LLOQ for participants with pre-vaccination hSBA ≥1:4 but <LLOQ, and a post-vaccination 4-fold rise for participants with pre-vaccination hSBA ≥LLOQ.


Composite hSBA response means hSBA ≥LLOQ for all 3 indicator Meningococcal B strains.

In a randomized, controlled clinical trial conducted in the U.K. among university students aged 18 through 24 years, hSBA responses in a subset of participants who received BEXSERO were measured 1 month and 11 months after the second dose (Table 3).
Table 3. Bactericidal Antibody Response Rates following 2 Doses of BEXSERO Administered 1 Month Apart to University Students in the U.K.a

<table>
<thead>
<tr>
<th>Strain (Antigen)</th>
<th>n</th>
<th>%</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>H44/76 (fHbp)</td>
<td>148</td>
<td>78</td>
<td>71, 85</td>
</tr>
<tr>
<td>5/99 (NadA)</td>
<td>148</td>
<td>94</td>
<td>89, 97</td>
</tr>
<tr>
<td>NZ98/254 (PorA P1.4)</td>
<td>147</td>
<td>67</td>
<td>58, 74</td>
</tr>
</tbody>
</table>

Composite hSBA Responsec,d

<table>
<thead>
<tr>
<th>Time Point</th>
<th>n</th>
<th>%</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline (pre-vaccination)</td>
<td>186</td>
<td>24</td>
<td>18,30</td>
</tr>
<tr>
<td>1 Month post-dose 2</td>
<td>147</td>
<td>88</td>
<td>82,93</td>
</tr>
<tr>
<td>11 Months post-dose 2</td>
<td>136</td>
<td>66</td>
<td>58,72</td>
</tr>
</tbody>
</table>

NCT01214850.

hSBA = Serum bactericidal activity measured using human complement, CI = Confidence Interval, fHbp = factor H binding protein, NadA = Neisserial adhesin A, PorA = Porin A protein, LLOQ = Lower limit of quantitation.

a Evaluable immunogenicity population (aged 18 through 24 years).
b ≥4-fold hSBA response is defined as: a post-vaccination hSBA ≥1:16 for participants with pre-vaccination hSBA <1:4, a post-vaccination titer at least 4-fold the LLOQ for participants with pre-vaccination hSBA ≥1:4 but <LLOQ, and a post-vaccination 4-fold rise for participants with pre-vaccination hSBA ≥LLOQ.
d Composite hSBA response means hSBA ≥LLOQ for all 3 indicator Meningococcal B strains.

15 REFERENCES
1. NCT01272180 (V102_03).
2. NCT00661713 (V72P10).
3. NCT01214850 (V72_29).
4. NCT01423084 (V72_41).

16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied

BEXSERO is available in 0.5-mL single-dose, disposable, prefilled TIP-LOK syringes (Luer Lock syringes) packaged without needles. TIP-LOK syringes are to be used with Luer Lock compatible needles.
The tip cap and rubber plunger stopper of the prefilled syringe are not made with natural rubber latex.

Table 4. Product Presentation for BEXSERO

<table>
<thead>
<tr>
<th>Presentation</th>
<th>Carton NDC Number</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-filled syringe</td>
<td>Carton of 10 syringes</td>
<td>58160-976-20 0.5-mL single-dose prefilled syringe NDC 58160-976-02</td>
</tr>
</tbody>
</table>

16.2 Storage and Handling

Do not freeze. Discard if the vaccine has been frozen.

Store refrigerated, at 36°F to 46°F (2°C to 8°C).

Protect from light.

Do not use after the expiration date.

17 PATIENT COUNSELING INFORMATION

Give the patient, parent, or guardian the Vaccine Information Statements, which are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (www.cdc.gov/vaccines).

Inform patients, parents, or guardians about:

- The importance of completing the immunization series.
- Reporting any adverse reactions to their healthcare provider.

BEXSERO, MENVEO, and TIP-LOK are trademarks owned by or licensed to the GSK group of companies.

The other brand listed is a trademark owned by or licensed to its owner and is not owned by or licensed to the GSK group of companies. The maker of this brand is not affiliated with and does not endorse the GSK group of companies or its products.
Manufactured by GSK Vaccines, Srl
Bellaria-Rosia 53018, Sovicille (SI), Italy
U.S. License No. 1617

Distributed by GlaxoSmithKline
Durham, NC 27701

©2023 GSK group of companies or its licensor.

BXS:7PI